

Address: 13502 Chimney Sweep Drive, Houston, TX 77041.

Date Revoked: October 31, 1997.

Reason: Surrendered license voluntarily.

License Number: 1843.

Name: Arabian National Shipping Corp.

Address: 146-42 Guy Brewer Blvd., Jamaica, NY 11434.

Date Revoked: September 4, 1997.

Reason: Failed to maintain a valid surety bond.

License Number: 3398.

Name: Azuma Multi-Trans U.S.A., Inc.

Address: 1001 Fourth Avenue, Suite 2305, Seattle, WA 98154.

Date Revoked: October 8, 1997.

Reason: Surrendered license voluntarily.

License Number: 4129.

Name: Barbara G. Chopin d/d/a Southern Cargo Logistics.

Address: 3445 North Causeway Boulevard, Suite 301, Metairie, LA 70002.

Date Revoked: October 8, 1997.

Reason: Failed to maintain a valid surety bond.

License Number: 3530.

Name: Bechtrans International, Inc.

Address: 343 North Oak Street, Inglewood, CA 90302.

Date Revoked: September 29, 1997.

Reason: Failed to maintain a valid surety bond.

License Number: 1576.

Name: Ben Federico.

Address: 8035 NW 67th Street, Miami, FL 33166.

Date Revoked: October 29, 1997.

Reason: Surrendered license voluntarily.

Bryant L. VanBrakle,

Director, Bureau of Tariffs, Certification and Licensing.

[FR Doc. 98-3003 Filed 2-5-98; 8:45 am]

BILLING CODE 6730-01-M

FEDERAL RESERVE SYSTEM

Notice of Proposals to Engage in Permissible Nonbanking Activities or to Acquire Companies that are Engaged in Permissible Nonbanking Activities; Correction

This notice corrects a notice (FR Doc. 98-1173) published on pages 2981 and 2982 of the issue for Tuesday, January 20, 1998.

Under the Federal Reserve Bank of New York heading, the entry for Greater Community Bancorp, Totowa, New York, is revised to read as follows:

A. Federal Reserve Bank of New York (Betsy Buttrill White, Senior Vice

President) 33 Liberty Street, New York, New York 10045-0001:

1. *Greater Community Bancorp*, Totowa, New Jersey; to acquire up to 9.9 percent of the outstanding stock of 1st Bergen Bancorp, Wood-Ridge, New Jersey, and thereby indirectly acquire South Bergen Savings Bank, Wood-Ridge, New Jersey, and thereby engage in operating a savings bank, pursuant to § 225.28(b)(4)(ii) of the Board's Regulation Y.

Comments on this application must be received by February 13, 1998.

Board of Governors of the Federal Reserve System, February 2, 1998.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 98-2900 Filed 2-5-98; 8:45 am]

BILLING CODE 6210-01-F

FEDERAL RESERVE SYSTEM

Notice of Proposals To Engage in Permissible Nonbanking Activities or To Acquire Companies That are Engaged in Permissible Nonbanking Activities

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y, (12 CFR Part 225) to engage *de novo*, or to acquire or control voting securities or assets of a company that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. The notice also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than February 20, 1998.

A. Federal Reserve Bank of Richmond (A. Linwood Gill III, Assistant Vice President) 701 East Byrd Street, Richmond, Virginia 23261-4528:

1. *First Union Corporation*, Charlotte, North Carolina; to retain 79.8 percent of the voting shares of Mentor Investment Group, LLC, Richmond, Virginia, that are held by Notificant's wholly owned

subsidiary, Wheat First Butcher Singer, Inc., Richmond, Virginia, and thereby engage in providing financial and investment advisory services, pursuant to § 225.28(b)(6) of the Board's Regulation Y, and providing administrative services to open-end investment companies ("mutual funds"). See *J.P. Morgan & Co., Inc.*, (Order dated December 8, 1997); *Bankers Trust New York Corporation*, 83 Fed. Res. Bull. 780 (1997); *Commerzbank AG*, 83 Fed. Res. Bull. 678 (1997); *The Governor and Company of the Bank of Ireland*, 82 Fed. Res. Bull. 1129 (1996); *Barclays PLC*, 82 Fed. Res. Bull. 158 (1996); *Mellon Bank Corporation*, 79 Fed. Res. Bull. 626 (1993). Notificant would engage in these activities in accordance with the limitations and condition previously established by the Board by regulation or order, with certain exceptions that are discussed in the notice.

Board of Governors of the Federal Reserve System, February 2, 1998.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 98-2901 Filed 2-5-98; 8:45 am]

BILLING CODE 6210-01-F

FEDERAL RESERVE SYSTEM

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: Board of Governors of the Federal Reserve System.

TIME AND DATE: 10:00 a.m., Wednesday, February 11, 1998.

PLACE: Marriner S. Eccles Federal Reserve Board Building, 20th and C Streets, N.W., Washington, D.C. 20551.

STATUS: Closed.

MATTERS TO BE CONSIDERED:

1. Personnel actions (appointments, promotions, assignments, reassignments, and salary actions) involving individual Federal Reserve System employees.

2. Any matters carried forward from a previously announced meeting.

CONTACT PERSON FOR MORE INFORMATION: Joseph R. Coyne, Assistant to the Board; 202-452-3204.

SUPPLEMENTARY INFORMATION: You may call 202-452-3206 beginning at approximately 5 p.m. two business days before the meeting for a recorded announcement of bank and bank holding company applications scheduled for the meeting; or you may contact the Board's Web site at <http://www.bog.frb.fed.us> for an electronic announcement that not only lists applications, but also indicates procedural and other information about the meeting.

Dated: February 4, 1998.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 98-3190 Filed 2-4-98; 12:45 pm]

BILLING CODE 6210-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 98F-0057]

Ciba Specialty Chemicals Corp.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Ciba Specialty Chemicals Corp. has filed a petition proposing that the food additive regulations be amended to provide for the safe use of calcium bis[monoethyl(3,5-di-*tert*-butyl-4-hydroxybenzyl)phosphonate] as a stabilizer for polyethylene phthalate polymers intended for use in contact with food.

FOR FURTHER INFORMATION CONTACT: Vir D. Anand, Center for Food Safety and Applied Nutrition (HFS-216), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-418-3081.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 8B4578) has been filed by Ciba Specialty Chemicals Corp., 540 White Plains Rd., Tarrytown, NY 10591-9005. The petition proposes to amend the food additive regulations in § 178.2010 *Antioxidants and/or stabilizers for polymers* (21 CFR 178.2010) to provide for the safe use of calcium bis[monoethyl (3,5-di-*tert*-butyl-4-hydroxybenzyl)phosphonate] as a stabilizer for polyethylene phthalate polymers, complying with 21 CFR 177.1630, intended for use in contact with food.

The agency has determined under 21 CFR 25.32(i) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

Dated: January 22, 1998.

Laura M. Tarantino,

Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 98-2909 Filed 2-5-98; 8:45 am]

BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 98D-0003]

FDA Modernization Act of 1997: Guidance for the Device Industry on Implementation of Highest Priority Provisions; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a guidance entitled "FDA Modernization Act of 1997: Guidance for the Device Industry on Implementation of Highest Priority Provisions; Availability." This guidance, generally referred to as the "Day-1 guidance" summarizes FDA's strategy for implementing the highest priority provisions of the FDA Modernization Act of 1997 (FDAMA) as it relates to the regulation of medical devices. The agency requests comments on this guidance.

DATES: Submit written comments by May 7, 1998.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857. Submit written requests for single copies of the guidance entitled "FDA Modernization Act of 1997: Guidance for the Device Industry on Implementation of the Highest Priority Provisions" to the Division of Small Manufacturers Assistance, Center for Devices and Radiological Health (HFZ-220), Food and Drug Administration, 1350 Piccard Dr., Rockville, MD 20850. Send two self-addressed adhesive labels to assist that office in processing your request, or fax your request to 301-443-8818. See the **SUPPLEMENTARY INFORMATION** section for electronic access to the guidance.

FOR FURTHER INFORMATION CONTACT: Joseph M. Sheehan, Center for Devices and Radiological Health (HFZ-1), Food and Drug Administration, 1350 Piccard Dr., Rockville, MD 20850, 301-443-4690.

SUPPLEMENTARY INFORMATION:

I. Background

The "Day-1 guidance" announced in this document summarizes FDA's strategy for implementing the highest priority provisions of the FDAMA (Pub. L. 105-115) as it relates to the regulation of medical devices. FDA identified these provisions as being of the highest priority for implementation because: (1) They become effective on or before February 19, 1998, the general effective date of the act; (2) they are expected to impact a large number of products/applications; or (3) they are of high interest to the device community. Unless an alternative method of implementation is specified in the statute, FDA generally plans to issue individual guidance documents to implement these provisions of the new law. The highest priority provisions of FDAMA identified in the guidance, and related sections in FDAMA, are:

- (1) Early collaboration on data requirements for clinical studies (sections 201 and 205),
- (2) Premarket approval application (PMA) collaborative review process (section 209),
- (3) Scope of review: labeling claims for PMA's (section 205),
- (4) PMA supplements for manufacturing changes (section 205),
- (5) Premarket notification exemptions (section 206),
- (6) Evaluation of automatic class III designation (section 207),
- (7) Device standards (section 204),
- (8) Scope of review: labeling claims for 510(k)'s (section 205),
- (9) 90-Day review of 510(k)'s (section 209),
- (10) Device tracking (section 211),
- (11) Postmarket surveillance (section 212), and
- (12) Dispute resolution (section 404).

The "Day-1 guidance" provides a section-by-section summary of each of these statutory provisions and describes FDA's general approach to implementing each such provision.

In accordance with FDA's Good Guidance Practices (62 FR 8961, February 27, 1997), this Level 1 guidance is being issued without prior public comment because it affects immediate implementation of new statutory requirements. Comments and suggestions regarding this guidance may be submitted by May 7, 1998. Unless specified otherwise, other guidances referenced in this guidance will also be issued as Level 1 guidances that become effective upon publication, with the opportunity to submit comments to the agency during the implementation stage.

This guidance represents the agency's current thinking on the implementation